RT Journal Article
SR Electronic
T1 Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.09.21253237
DO 10.1101/2021.03.09.21253237
A1 Dite, Gillian S.
A1 Murphy, Nicholas M.
A1 Allman, Richard
YR 2021
UL http://medrxiv.org/content/early/2021/03/28/2021.03.09.21253237.abstract
AB Clinical and genetic risk factors for severe COVID-19 are often considered independently and without knowledge of the magnitudes of their effects on risk. Using SARS-CoV-2 positive participants from the UK Biobank, we developed and validated a clinical and genetic model to predict risk of severe COVID-19. We used multivariable logistic regression on a 70% training dataset and used the remaining 30% for validation. We also validated a previously published prototype model. In the validation dataset, our new model was associated with severe COVID-19 (odds ratio per quintile of risk=1.77, 95% confidence interval [CI]=1.64, 1.90) and had excellent discrimination (area under the receiver operating characteristic curve=0.732, 95% CI=0.708, 0.756). We assessed calibration using logistic regression of the log odds of the risk score, and the new model showed no evidence of over- or under-estimation of risk (α=−0.08; 95% CI=−0.21, 0.05) and no evidence or over- or under-dispersion of risk (β=0.90, 95% CI=0.80, 1.00). Accurate prediction of individual risk is possible and will be important in regions where vaccines are not widely available or where people refuse or are disqualified from vaccination, especially given uncertainty about the extent of infection transmission among vaccinated people and the emergence of SARS-CoV-2 variants of concern.Key resultsAccurate prediction of the risk of severe COVID-19 can inform public heath interventions and empower individuals to make informed choices about their day-to-day activities.Age and sex alone do not accurately predict risk of severe COVID-19.Our clinical and genetic model to predict risk of severe COVID-19 performs extremely well in terms of discrimination and calibration.Competing Interest StatementGSD, NMM, and RA are employees of Genetic Technologies Limited. Genetic Technologies Limited had no role in the conceptualization, design, data analysis, decision to publish or preparation of the manuscript. Aspects of this manuscript are covered by Provisional Patent Application AU_2021900392 (pending), Methods of assessing risk of developing a severe response to Coronavirus infection. GSD, NMM, and RA are named inventors on the patent application, which is assigned to Genetic Technologies Limited.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Biobank has Research Tissue Bank approval (REC #11/NW/0382) that covers analysis of data by approved researchers. All participants provided written informed consent to the UK Biobank before data collection began. This research has been conducted using the UK Biobank resource under Application Number 47401.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe used data from the UK Biobank (under Application Number 47401) for these analyses and do not have permission to share the data. Researchers wishing to access the data used in this study can apply directly to the UK Biobank at https://www.ukbiobank.ac.uk/register-apply/. https://www.ukbiobank.ac.uk/register-apply/